Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk (NVO) announced an unsolicited proposal to acquire Metsera, Inc. The offer includes cash consideration of 56.50 USD per share, equal to an approximate aggregated equity value of 6.5 billion USD (approximate enterprise value of 6.0 billion USD), plus contingent value rights (CVRs) of up to 21.25 USD per share (an approximate aggregated value of up to 2.5 billion USD) tied to clinical and regulatory milestones.
The cash consideration would be paid at signing in exchange for non‑voting preferred stock representing 50% of Metsera’s share capital, and the CVRs would be issued at closing in exchange for the remaining shares. Novo Nordisk states that Metsera’s early and development‑stage incretin and non‑incretin peptide programs are complementary to its strategy in obesity and diabetes. The proposal is subject to review by Metsera’s board.
Novo Nordisk A/S called a fully electronic Extraordinary General Meeting to elect new members to the Board of Directors. The meeting will be held on 14 November 2025 at 14:00 CET.
The agenda proposes electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and Britt Meelby Jensen, Mikael Dolsten and Stephan Engels as board members, with Kasim Kutay continuing. Several current directors will not stand for election. All proposals may be adopted by a simple majority of votes.
Record date for participation and voting rights is 7 November 2025 at 23:59 CET. Registration and proxy deadlines are 10 November 2025 at 23:59 CET, and votes by correspondence must be received by 13 November 2025 at 09:00 CET. The Company’s share capital is DKK 446,500,000, split into A shares DKK 107,487,200 (10 votes per DKK 0.01) and B shares DKK 339,012,800 (1 vote per DKK 0.01).
Novo Nordisk A/S will convene an Extraordinary General Meeting to elect new members of the Board of Directors on 14 November 2025. The decision follows dialogue with the Novo Nordisk Foundation about board composition; the Foundation holds the majority of votes. The Board concluded that electing new members via an EGM is in the best interest of the company and shareholders to provide clarity on future governance.
Chair Helge Lund, Vice Chair Henrik Poulsen, and independent directors Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay will not stand for election at the EGM. Kasim Kutay (not independent) and employee‑elected members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board.
Novo Nordisk will host an investor conference call at 15:00 CEST on 21 October 2025, with a dial‑in link available on the company’s investor website.
Novo Nordisk is implementing a global transformation to speed decision-making and redirect resources toward diabetes and obesity growth opportunities. The company intends to reduce about 9,000 roles of its ~78,400 positions (approximately 5,000 of those in Denmark) and expects to deliver DKK 8 billion of annualised savings by the end of 2026. Management will incur one-off restructuring costs of DKK 8 billion, and it updated its full-year 2025 operating profit growth outlook to 4–10% at constant exchange rates, down from the prior 10–16% outlook—about a 6 percentage point reduction versus the August outlook. The transformation is presented as a response to recent slowdown in growth and increased organisational complexity, with additional initiatives planned to improve focus, performance culture and cost efficiency.
Novo Nordisk A/S filed a report showing trading in its American Depositary Receipts (ADRs) by a member of the board of directors. Board member Christina Law purchased Novo Nordisk ADRs on the New York Stock Exchange.
The filing states that she carried out several purchases on 18 August 2025 at prices of DKK 349.06 for 952 ADRs, DKK 349.04 for 598 ADRs and DKK 349.03 for 800 ADRs. In total, this represents an aggregated volume of 2,350 ADRs for a total consideration of DKK 820,252.49, reported in accordance with European market abuse rules.
Novo Nordisk disclosed that Ludovic Helfgott, Executive Vice President, sold 12,000 Novo Nordisk B shares at DKK 326 per share on Nasdaq Copenhagen on 2025-08-08, for an aggregate amount of DKK 3,912,000. The company reported the transaction under Article 19 of Regulation No. 596/2014, with the sale recorded as an initial notification by the named executive.
The announcement also reiterates basic company information: Novo Nordisk markets its B shares on Nasdaq Copenhagen and ADRs on the New York Stock Exchange under the ticker NVO, employs about 78,400 people, and sells products in roughly 170 countries.
Form 6-K insider transaction report
On 8 Aug 2025, Novo Nordisk A/S (NVO) disclosed a managerial transaction under EU Market Abuse Regulation Article 19. Executive Vice President Ludovic Helfgott sold 28,710 class B shares (ISIN DK0062498333) on Nasdaq Copenhagen on 7 Aug 2025 at DKK 295.00 per share, generating gross proceeds of DKK 8,469,450.
The filing contains no financial results, strategic updates or additional insider dealings; it solely records this single transaction. Accordingly, investors receive limited insight into current operating performance, and the trade’s materiality is modest relative to Novo Nordisk’s market capitalisation.
Novo Nordisk (NVO) filed a Form 6-K disclosing insider transactions under EU Market Abuse Reg. 19. Executive Vice President Martin Holst Lange sold company B-shares on 7 Aug 2025 in two separate trades:
- 74 shares at DKK 316.75 (total DKK 23,439.50)
- 13,950 shares at DKK 316.48 (total DKK 4,414,898.43)
The combined sale amounts to 14,024 shares valued at DKK 4.44 million (≈ USD 0.65 million). One trade was executed through Citigroup Global Markets Europe AG; the larger block was carried out outside a trading venue. No purchases, option exercises, or other corporate events were reported, and no financial performance data accompanied the filing. The disclosure fulfills statutory reporting obligations but does not indicate any change in strategy, guidance, or fundamentals.
Event: On 4 Aug 2025 Novo Nordisk A/S (NYSE: NVO) filed a Form 6-K after receiving an unsolicited “mini-tender” from TRC Capital Investment Corp. to buy up to 2 million American Depositary Shares (ADSs), representing less than 0.045 % of the company’s total share capital. The offer applies only to ADSs, not ordinary shares.
Company stance: Novo Nordisk remains neutral, does not endorse the bid and advises holders to obtain current quotes, consult advisers, scrutinise the offer terms (including any price revisions) and act with caution. Management emphasises that mini-tenders target under 5 % of shares and therefore bypass full U.S. SEC tender-offer disclosure and procedural safeguards. Links to relevant SEC investor alerts and broker-dealer guidance are provided.
Investor impact: Because the offer covers an immaterial stake, no change in control, capital structure or operating fundamentals is expected. The filing’s primary purpose is to protect shareholders by flagging potential risks associated with mini-tender mechanics; it contains no financial results, guidance or strategic updates.